These data collectively revealed that the enhancement of the tumor-rejecting effect after LR-DPVB treatment was largely dependent on the magnitude of intratumoral CD8+ Tex, which featured with potent effector function and cytolytic capacity. The gene discussed is CD8A; the disease is neoplasm.